SGLT-2i 是治疗 2 型糖尿病、心力衰竭和慢性肾脏疾病的新药,通过阻断近端小管中钠依赖性葡萄糖共转运蛋白,减少其对葡萄糖的重吸收而降低血糖。尽管使用 SGLT-2i 的患者中尿路感染的发生率相对较低,但与其使用相关的严重尿路感染,包括气肿性肾盂肾炎,在医学文献中已有报道。 SGLT-2i 引起的泌尿生殖道局部葡萄糖...
Conclusions: The treatment of HFpEF has made progress, but there is still work to be done. Now, SGLT2 inhibitor therapy can be used to further help with symptom control and reduce overall hospitalizations for heart failure.doi:10.1177/10600280231189508Starr, Jessica A.Pinn...
other studies found that the anti-proliferative effects of canagliflozin are not influenced by glucose-update or the level of SGLT2 expression44. Papadopoli et al.44, found that Canagliflozin is a potent inhibitor of mitochondrial respiration and total ATP production...
SGLT inhibitor treatment could restore axonal varicosities and organelles, which may lead to improved gastrointestinal functions in HFD-induced obesity as well as diabetes.Similar content being viewed by others Prolonged high fat diet ingestion, obesity, and type 2 diabetes symptoms correlate with ...
www.nature.com/scientificreports OPEN Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis received: 20 January 2016 without improving albuminuria inaccepted:03May2016 diabetic db/db micePublished:26May2016 Linda A. Gallo1, Micheal S. Ward1,...
Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way...
Method for the treatment of Obesity sglt2 using an inhibitor.WASHBURN, WILLIAMWHALEY, JEANMALDONADO, MARIOLIST, JAMES F.FIEDOREK, FREDERICK T.
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012; 35 :1473–1478.Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, ...
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, double‑blind, placebo‑controlled pilot study. Diabetes Care 2015;38:412‑9.Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, Bogle A, Iqbal N, List J, ...
Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a...